This ongoing study evaluated the diagnostic accuracy of HPAO-SPECT and 1HMRS in the diagnosis of Alzheimer's disease. Both methods proved highly specific for diagnosis but post mortem validation of the clinical diagnosis is required for a final judgement on 1HMRS and HMPAO-SPECT.
LaaksoMPPartanenK: Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology46 (3): 678–81, 1996.
2.
JobstKAHindleyNJ: The diagnosis of Alzheimer's disease: Ce question of image?J Clin Psychiatry55: 22–31, 1994.
3.
MessaCPeraniD: High-resolution Technetium-99m-HMPAO-SPECT in patients with probable Alzheimer's disease: Comparison with Fluorine-18-FDG-PET. J Nucl Med35: 210–216, 1994.
4.
HerminghausSFröhlichL: Störung der Signaltrans-duktion bei Morbus Alzheimer. Klinische Neuroradie1: 34, 1998.
5.
GeorgeMSNetterTAPostRM: SPECT and PET imaging in mood disorders. J Clin Psychiatry54: 6–13, 1993.
6.
RingH: Brain SPECT in neuropsychiatry-activation studies in health and disease. New trends in nuclear neurology and psychiatry. Eds. LibbeyI and Company, London1993: 119–131.
LaubenbergerJHaussingerD: HIV related metabolic abnormalities in the brain: Depiction with proton MR spectroscopy with short echo Times. Radiology199: 805–810, 1996.
9.
JollesJBothmerJ: Phosphatidylinositol hinase is reduced in Alzheimer's disease. J Neurochem38: 2326–2329, 1992.
10.
StokesCEHawthorneJN: Reduced phosphoinositide concentrations in auterior temporal cortex of Alzheimer disease brains. J Neurochem48: 1018–1021, 1986.
